Meeting
2023 ASCO Genitourinary Cancers Symposium
Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.
Authors
John McGrane
Royal Cornwall Hospital NHS Trust, Cornwall, United Kingdom
John McGrane , Ricky Frazer , Amit Bahl , Dominique Siobhan Parslow , Salma Moona Alam , Sarah Nelms , Ahmed Shaheen , Anna Lydon , Dhruv Abhi , Gemma Clements , Heather Keenan , Yifei Wang , Victoria Ford , Amarnath Challapalli , Alexandra Ferrera , Sin-yu Moorcraft , Wael Mohamed , Eleanor Jones , Justin KH Liu , Gihan Ratnayake
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 689)
DOI
10.1200/JCO.2023.41.6_suppl.689
Abstract #
689
Poster Bd #
J2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2021 Genitourinary Cancers Symposium
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani